Business context and reporting period
Filing/entity mismatch: The request identifies Decoy Therapeutics Inc., but the supplied Form 10-K is for Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX). Verify that this is the intended filing. It covers the fiscal year ended December 31, 2022; figures below are annual, not standalone fourth-quarter results.
Salarius is a clinical-stage oncology biotechnology company with no approved products or product-sale revenue. Its programs include seclidemstat (SP-2577), an LSD1 inhibitor, and SP-3164, a targeted protein degrader acquired in January 2022.
Key financial metrics
| Metric | 2022 | 2021 |
|---|---|---|
| Grant revenue | $0 | $1.84 million |
| Research and development expense | $15.84 million | $8.55 million |
| General and administrative expense | $7.14 million | $6.10 million |
| Goodwill impairment | $8.87 million | $0 |
| Net loss | $31.61 million | $12.77 million |
| Basic and diluted loss per share | $14.88 | $7.72 |
| Net cash used in operating activities | $17.60 million | $10.20 million |
| Cash and cash equivalents at year-end | $12.11 million | $29.21 million |
At December 31, 2022, working capital was $10.3 million, total assets were $14.65 million, total liabilities were $4.27 million, and stockholders’ equity was $10.38 million. The balance sheet reports no debt; the filing also reports no note-payable payments in 2022. No product-sales revenue was reported, so a product-sales margin is not meaningful.
Material changes versus prior year
- Net loss widened by $18.84 million, reflecting higher R&D spending, no grant revenue in 2022, and an $8.87 million goodwill impairment.
- R&D expense rose $7.29 million, mainly due to the DeuteRx asset acquisition and SP-3164 development; lower SP-2577 costs partly offset the increase.
- Cash declined $17.11 million. Operating cash use increased, while 2021 financing proceeds of $28.30 million were replaced by only $1.99 million of net financing cash in 2022.
- The company completed a 1-for-25 reverse stock split on October 14, 2022; historical share and per-share amounts in the filing are adjusted for it.
Outlook, risks and unusual items
- Going concern and liquidity: Management and the auditor disclosed substantial doubt about the company’s ability to continue as a going concern. Management estimated year-end cash would fund operations through the third quarter of 2023, while also stating existing funds might not cover one year from the report/financial-statement issuance date. Additional capital is required; there is no assurance it will be available on acceptable terms.
- Clinical risk: New enrollment in the seclidemstat Phase 1/2 Ewing sarcoma and FET-rearranged sarcoma trial was paused after a patient death classified as a suspected unexpected serious adverse reaction. The FDA placed the trial on partial clinical hold on November 1, 2022. Patients already receiving treatment could continue after consulting their physicians. The related MD Anderson MDS/CMML study also paused enrollment and was placed on partial hold.
- Development plans: Management planned to seek an SP-3164 IND in the first half of 2023 and begin a Phase 1/2 trial in the second half; these were forward-looking plans, not reported outcomes. The filing says SP-3164 was in IND-enabling studies.
- Funding and dilution: On February 15, 2023, the company received $1.5 million from CPRIT, bringing cumulative disbursements to about $16.0 million; CPRIT receivable was about $0.1 million as of March 24, 2023. From January 27 through March 24, 2023, the company sold 142,499 shares through its at-the-market program for about $0.4 million gross.
- Other unusual items: The January 2022 SP-3164 acquisition had a stated aggregate purchase price of $2.0 million ($1.5 million cash and 40,000 shares valued at about $0.5 million); acquired in-process R&D without alternative future use was expensed. A board member had a relationship with DeuteRx, disclosed in the filing. The CPRIT grant may entail repayment or future revenue-sharing obligations under specified conditions.
- The company has no manufacturing or sales organization and relies on third parties for development and manufacturing. Clinical, financing, patient-enrollment, regulatory, intellectual-property, and future commercialization risks are material.
Most important facts for investors to verify
- Confirm the filing belongs to the intended company: the supplied filing is Salarius Pharmaceuticals, not Decoy Therapeutics.
- Check subsequent filings for the status of the FDA partial clinical holds, seclidemstat enrollment, and any safety updates.
- Verify current cash, financing raised, share count, and actual cash runway; the filing’s runway estimates are dated and additional equity issuance may dilute holders.
- Review whether SP-3164’s planned IND and clinical-trial milestones occurred, and whether CPRIT’s grant extension or receivable was resolved.
- Assess the goodwill impairment, DeuteRx acquisition accounting and related-party disclosure, and any contingent milestone, royalty, or CPRIT repayment/revenue-sharing obligations.
The auditor gave an unqualified opinion on the financial statements but included a going-concern explanatory paragraph. Management reported disclosure controls and internal control over financial reporting were effective as of December 31, 2022; the auditor was not engaged to opine on internal-control effectiveness.